Form 4: PMV Pharmaceuticals Director Richard Heyman Acquires Stock Options

Director Richard A. Heyman acquired 67,500 stock options in PMV Pharmaceuticals, Inc. on June 6, 2024, according to a Form 4 filing.

Summary

• Richard A. Heyman, a director of PMV Pharmaceuticals, Inc., acquired 67,500 stock options on June 6, 2024.
• The exercise price of these options is $1.65.
• 22,500 shares vest on the earlier of June 6, 2025, or the day prior to the company's next annual meeting of stockholders.
• The remaining 45,000 shares vest in 36 equal monthly installments starting on July 6, 2024.
• The options expire on June 5, 2034.
• A power of attorney was executed on January 5, 2024, appointing David H. Mack, Robert Ticktin, and Michael Carulli to handle SEC filings related to Section 16 of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The acquisition of stock options by a director is generally viewed as a neutral to slightly positive signal.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates